GSK PLC Sponsored ADR (GSK) vs Organon & Co. (OGN)
GSK PLC Sponsored ADR and Organon & Co. are both Drug Manufacturers General companies. GSK PLC Sponsored ADR is the larger, with a market value of $100.1B against $3.6B — 27.8× the size. GSK PLC Sponsored ADR trades at the lower P/E: 15.3× against 17.4×. GSK PLC Sponsored ADR grew revenue faster over the last twelve months: 8.72% against −2.45%. GSK PLC Sponsored ADR has the higher net margin (14.6% vs 3.41%) and the higher return on invested capital (12.6% vs 6.11%). Both pay a dividend; Organon & Co. yields more (6.88% vs 3.66%). Across the 23 metrics below, GSK PLC Sponsored ADR leads on 15 and Organon & Co. on 8.
Valuation
Profitability
| Metric | GSK | OGN | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 72.75% | 52.68% | 72.77% |
| Operating margin | 19.55% | 13.45% | 18.90% |
| Net margin | 14.58% | 3.41% | 8.27% |
| Free cash flow margin | 17.18% | 7.57% | 17.25% |
| Return on equity | 30.74% | 24.04% | 6.97% |
| Return on assets | 8.01% | 1.57% | 2.76% |
| Return on invested capital | 12.58% | 6.11% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack